Success examples
Fluorophore-Labeled Pyrrolones Targeting the Intracellular Allosteric Binding Site of the Chemokine Receptor CCR1

Toy L., Huber M. E., Lee M., Alonso Bartolomé A., Ortiz Zacarías N. V., Nasser S., Scholl S., Zlotos D. P., Mandour Y. M., Heitman L. H., Szpakowska M., Chevigné A., Schiedel M.

ACS Pharmacol Transl Sci. 2024, 7(7):2080-2092.

Success examples
Functional characterization of pathway inhibitors for the ubiquitin-proteasome system (UPS) as tool compounds for CRBN and VHL-mediated targeted protein degradation

Schwalm M. P., Menge A., Elson L., Greco F. A., Robers M. B., Müller S., Knapp S.

ACS Chem Biol. 2025, 20(1):94-104.

Success examples
Sex Matters–Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer

Schulz B., Leitner E., Schreiber T., Lindner T., Schwarz R., Aboutara N., Ma Y., Ecobar H. M., Palme R., Hinz B., Vollmar B., Zechner D.

Cancers (Basel). 2024, 16(10):1901.

Success examples
Pharmacological inhibition of cathepsin S and of NSPs-AAP-1 (a novel, alternative protease driving the activation of neutrophil serine proteases)

Domain R., Seren S., Jerke U., Makridakis M., Chen KJ., Zoidakis J., Rhimi M,, Zhang X., Bonvent T., Croix C., Gonzalez L., Li D., Basso J., Paget C., Viaud-Massuard MC., Lalmanach G., Shi GP., Aghdassi A., Vlahou A., McDonald PP., Korkmaz B.

Biochemical Pharmacology 2024, 229:116114.

Success examples
Aurora B kinase inhibition intensifies cisplatin cytotoxicity in MCF7 breast cancer cells

Askan R., Gundogdu R.

EJM. 2024, 63(3):410-21.